[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=f72ebc790cd5dc2b7016f543f8dd72cd393189005ce40d8b6c44ef13526a5dfe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736268120,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 132325437,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=f72ebc790cd5dc2b7016f543f8dd72cd393189005ce40d8b6c44ef13526a5dfe"
    }
  },
  {
    "ts": null,
    "headline": "Vertex, startup Orna to partner on gene editing research",
    "summary": "The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.",
    "url": "https://finnhub.io/api/news?id=3ed405aef7f32f8f789a02afc9fbb6143307121bbb0ae4cfc48e1362c5e20bb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736252391,
      "headline": "Vertex, startup Orna to partner on gene editing research",
      "id": 132304363,
      "image": "https://imgproxy.divecdn.com/C-892h3p5lr2Zt4br4ikUquWE6YXvZGAkfTDE7aaWto/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CT1NfSFFfZXh0ZXJpb3JfVmVydGV4LmpwZw==.webp",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.",
      "url": "https://finnhub.io/api/news?id=3ed405aef7f32f8f789a02afc9fbb6143307121bbb0ae4cfc48e1362c5e20bb1"
    }
  },
  {
    "ts": null,
    "headline": "Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)",
    "summary": "Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to utilize Orna's novel and proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with SCD and TDT.",
    "url": "https://finnhub.io/api/news?id=ac351f928d5b7755fb03e9c8ac6118178043b8d4bd69fd9cdfd60fa4ba5556f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736251200,
      "headline": "Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)",
      "id": 132298862,
      "image": "https://media.zenfs.com/en/prnewswire.com/304c20486dafc7039794e2602467bb6a",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to utilize Orna's novel and proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with SCD and TDT.",
      "url": "https://finnhub.io/api/news?id=ac351f928d5b7755fb03e9c8ac6118178043b8d4bd69fd9cdfd60fa4ba5556f9"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
    "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
    "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736249479,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
      "id": 132302431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
      "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    }
  }
]